Literature DB >> 29414258

Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.

Vivek Narayan1,2, Bonnie Ky3,2,4.   

Abstract

There is growing awareness of the overlap between oncologic and cardiovascular (CV) diseases, including a wide range of CV effects of anticancer therapies. As novel anticancer therapeutics become available and cancer survival outcomes improve, the CV implications of cancer therapy become increasingly important. In addition to outlining the CV effects of commonly used cancer therapies and their consequences for long-term survivorship, this review highlights the recent efforts to improve the risk prediction and prevention of CV toxicity through the evaluation of sensitive measures for early toxicity detection and the implementation of cardioprotective strategies.

Entities:  

Keywords:  biomarkers; cardio-oncology; cardiotoxicity; heart failure; risk factors; survivorship

Mesh:

Substances:

Year:  2018        PMID: 29414258      PMCID: PMC6722326          DOI: 10.1146/annurev-med-041316-090622

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  10 in total

Review 1.  Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease.

Authors:  Jonathan A Kirk; Joseph Y Cheung; Arthur M Feldman
Journal:  J Clin Invest       Date:  2021-08-16       Impact factor: 19.456

Review 2.  Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.

Authors:  Vivek Narayan; Elizabeth W Thompson; Biniyam Demissei; Jennifer E Ho; James L Januzzi; Bonnie Ky
Journal:  J Am Coll Cardiol       Date:  2020-06-02       Impact factor: 24.094

3.  Basic cardiovascular risk assessment in naïve patients with colon cancer.

Authors:  Liliana Radulescu; Lucretia Avram; Elena Buzdugan; Dana Crisan; Alin Grosu; Cristiana Grapa; Laurentiu Stoicescu; Valer Donca; Sorin Crisan; Valentin Militaru; Anca Buzoianu; Dan Radulescu
Journal:  Exp Ther Med       Date:  2022-03-09       Impact factor: 2.447

4.  Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology Service.

Authors:  Hasan Ali Farhan; Israa Fadhil Yaseen
Journal:  Front Cardiovasc Med       Date:  2021-11-24

5.  Where are We Going with Natural Products? Exploring the True Potential of New Plant-Based Drugs in the Cardiovascular Field.

Authors:  Artur Santos-Miranda
Journal:  Arq Bras Cardiol       Date:  2022-08       Impact factor: 2.667

Review 6.  Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments.

Authors:  Guoxia Zhang; Chao Yuan; Xin Su; Jianzhen Zhang; Priyanka Gokulnath; Gururaja Vulugundam; Guoping Li; Xinyu Yang; Na An; Can Liu; Wanli Sun; Hengwen Chen; Min Wu; Shipeng Sun; Yanwei Xing
Journal:  Front Cardiovasc Med       Date:  2022-06-13

Review 7.  Acquired and modifiable cardiovascular risk factors in patients treated for cancer.

Authors:  Gary S Beasley; Jeffrey A Towbin
Journal:  J Thromb Thrombolysis       Date:  2020-09-12       Impact factor: 2.300

8.  Importance of cardio-oncology. How to detect suclinical heart failure.

Authors:  Jesús De Rubens-Figueroa; Rocío Cárdenas-Cardós
Journal:  Arch Cardiol Mex       Date:  2021

Review 9.  Challenges and Management of Acute Coronary Syndrome in Cancer Patients.

Authors:  Isabela Bispo Santos da Silva Costa; Fernanda Thereza de Almeida Andrade; Diego Carter; Vinicius B Seleme; Maycon Santos Costa; Carlos M Campos; Ludhmila Abrahão Hajjar
Journal:  Front Cardiovasc Med       Date:  2021-06-09

Review 10.  The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review.

Authors:  Fatemeh Jafari; Afsane Maddah Safaei; Leila Hosseini; Sanaz Asadian; Tara Molanaie Kamangar; Fatemeh Zadehbagheri; Nahid Rezaeian
Journal:  Heart Fail Rev       Date:  2020-10-07       Impact factor: 4.214

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.